Monthly Stock Report: Thermo Fisher Scientific Inc. (TMO)
Publication Date: September 22, 2024
Company Overview
Thermo Fisher Scientific Inc. (TMO), headquartered in Waltham, Massachusetts, is a premier player in the healthcare sector, specifically within the Diagnostics and Research industry. Established in 1956, TMO specializes in delivering life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products. With a strong global presence spanning North America, Europe, and Asia-Pacific, the company serves a diverse clientele in pharmaceuticals, biotechnology, academia, and government sectors. TMO’s extensive portfolio plays a critical role in advancing drug and vaccine development as well as diagnostic applications for various diseases.
Financial and Market Outlook
The Diagnostics and Research industry is emerging as a pivotal investment opportunity, earning a strong buy recommendation from analysts. With total revenues reaching approximately $42.35 billion, the sector demonstrates solid financial health and significant growth potential. Analysts are optimistic, setting a high price target of $767 for TMO, indicating a favorable shift. The current trading price of $613.69, alongside a projected mean target price of $644.96, highlights a potential upside for investors.
A total of 381,996,000 shares are outstanding, with a short position comprising only 0.93% of the float, suggesting investor confidence in TMO’s stability. Despite the absence of specific EBITDA data, analysts maintain a mean recommendation score of 2.0, reflecting a positive consensus on the stock’s future performance.
Stock Performance and Recommendations
Recent updates indicate that TMO’s stock is positioned well above its fifty-day average of $598.235, indicating strong short-term momentum. Over the past year, the stock fluctuated significantly, reaching a fifty-two week high of $627.88, suggesting potential resistance in the near term. Conversely, a fifty-two week low of $415.60 showcases the stock’s volatility and remarkable recovery, underscoring its upward trend.
With 24 analysts providing insights, there is considerable agreement regarding TMO’s strong projection for growth, making it an attractive option for potential investors. The price predictions ranging from a low of $565 to a high of $767 affirm TMO’s potential for continued success in the evolving healthcare landscape.
In conclusion, with robust revenue figures, a strong analyst consensus, and a promising market outlook, Thermo Fisher Scientific Inc. is positioned as a compelling investment in the Diagnostics and Research sector.
| Metric | Value |
|---|---|
| Market Cap | $234.4b |
| Total Debt | $35.4b |
| Total Cash | $8.8b |
| Shares Outstanding | 382.0m |
| Float Shares | 381.1m |
Disclaimer:
The information provided in this monthly report is for informational purposes only and should not be construed as financial, investment, or trading advice. AltStation.io does not guarantee the accuracy, completeness, or timeliness of the data and analyses presented. The content is based on publicly available information, and while we strive to ensure its accuracy, errors and omissions may occur.
Investing in stocks, cryptocurrencies, and other financial instruments involves significant risk, including the potential loss of principal. Past performance is not indicative of future results. Readers should conduct their own research and consult with a qualified financial advisor before making any investment decisions. AltStation.io and its affiliates are not responsible for any losses incurred as a result of using this report.
By using this report, you acknowledge that you understand and accept these terms.